Cell Recovery Calculators

0 calculators tagged with “Cell Recovery”

Cell recovery refers to the proportion of viable cells retrieved after a processing step such as thawing from cryopreservation, centrifugation, or immunomagnetic selection. It is expressed as: (viable cells recovered / viable cells input) × 100. High cell recovery is critical in cell therapy manufacturing, biobanking, and research to ensure sufficient cells for downstream applications. Losses occur through mechanical damage, osmotic stress, and apoptosis triggered by the process. Tracking recovery at each step identifies where losses occur and guides protocol optimization.

All Calculators

No calculators found for this topic.

Calculating Cell Recovery

% Recovery = (viable cells out / viable cells in) × 100

Both counts use Trypan blue exclusion or an automated viability counter. If you start with 50 × 10⁶ viable cells and recover 38 × 10⁶ after processing, recovery = (38/50) × 100 = 76%. Track recovery at each step to identify the bottleneck in your process.

Recovery After Cryopreservation

Cells frozen in 10% DMSO using controlled-rate cooling (−1°C/min) and stored in liquid nitrogen typically recover 70–90% post-thaw viability for robust cell lines. Key factors: pre-freeze viability (should be >90%), DMSO concentration, freezing rate, and thaw protocol. Rapid thaw at 37°C and immediate DMSO dilution minimize post-thaw losses.

Recovery After Centrifugation

Excessive centrifugal force or duration damages cells. For most mammalian cell lines, 200–400 × g for 5–10 min is standard for pelleting without significant damage. Gentle resuspension post-centrifugation prevents mechanical disruption of aggregated cells.

Cell Therapy Applications

GMP cell processing must document recovery at each step. A typical CAR-T manufacturing process expects 70–80% recovery through leukapheresis, T cell selection, activation, and transduction. Cumulative recovery across steps determines the final product yield and whether sufficient cells are available for the patient dose.

Glossary

Cell Recovery (%)
The percentage of viable cells retrieved after a processing step: (viable cells out / viable cells in) × 100; key metric in cell therapy manufacturing and biobanking.
Post-thaw Viability
The percentage of live cells in a cryopreserved sample immediately after thawing; a measure of cryopreservation protocol quality.
DMSO (Dimethyl Sulfoxide)
The most widely used cryoprotectant at 10% v/v; prevents ice crystal formation during freezing but is cytotoxic at room temperature and must be washed out promptly after thawing.

Frequently Asked Questions

Cell recovery (%) = (viable cells recovered / viable cells before processing) × 100. Count viable cells before and after each step using Trypan blue exclusion or an automated counter reporting viability. Track both total cell count and viability percentage — 80% recovery with 95% viability is far better than 90% recovery with 50% viability. Always document both metrics in your lab notebook and batch records.

For established cell lines (HeLa, CHO, Jurkat), 80–95% post-thaw viability is typical. For primary cells (T cells, stem cells, hepatocytes), 70–85% is acceptable. Recovery below 60% suggests problems with the freeze-thaw protocol. Consider adjusting DMSO concentration, cooling rate, pre-freeze cell health, or thaw speed. Post-thaw viability measured immediately overestimates functional recovery since some cells die over the following hours.

DMSO at 10% v/v is the standard cryoprotectant — it penetrates cells and prevents ice crystal formation. However, DMSO is cytotoxic at room temperature. Cells must be cooled immediately after adding DMSO, and the compound must be washed out quickly after thawing. Extended DMSO exposure at 37°C damages membranes and reduces recovery. For DMSO-sensitive cell types, lower concentrations (5–7.5%) or alternative cryoprotectants (glycerol, trehalose) may help.

In autologous cell therapy (e.g., CAR-T), the patient's own cells are the only starting material — there is no alternative source. Each processing step that loses cells reduces the final yield. If cumulative recovery falls too low, there may not be enough cells for a therapeutic dose. GMP batch records document recovery at every step, and processes failing recovery thresholds trigger investigation and potential batch failure.